Sakamakon farko akan kwayoyin da ke da dangantaka da CGRP da kuma mai karɓar sa
Peptide na kwayoyin Calcitonin (CGRP), wani sinadaran da wasu kwayoyin halittu suka samar da su a cikin tsarin kulawa ta tsakiya da tsarin jin dadin jiki, an yi imanin cewa suna taka muhimmiyar rawa a cikin migraines. Ba wai kawai an gano wannan furotin a lokacin hare-haren ƙaura ba, amma magance jin zafi na migraine tare da magani na migraine wanda ake kira triptan ya dace da daidaitaccen tsarin CGRP a cikin jini.
A lokacin da ake kai hare-haren ƙaura, yana yiwuwa wasu ƙwayar ƙaura suna haifar da jini a kusa da kwakwalwa don dilar, ko kuma fadada. Wadannan jinin cranial yaduwanci sannan kunna nau'ikan ƙwayoyi masu kamala. Da zarar an kunna, magunguna masu jijiyar jiki suna aika sako zuwa ga kwakwalwa - abin da ke haifar da sakin sunadarai daban-daban, kamar CGRP.
Cibiyar ta CGRP tana haifar da karawar ƙarar jini da kuma wani abu da ake kira "ƙananan ƙonewa". Yayin da migraine ke ci gaba da ci gaba, kwakwalwar kwakwalwa ta zama abin ƙwarewa. Wannan yana haifar da mummunan yunkuri na ciwo mai tsanani da kuma karuwa a cikin yanayin.
Mene Ne Nazarin Farko akan Gidan Gida?
Nazarin II na II - nazarin da aka yi a kan ƙananan marasa lafiya don ƙayyade amfanin da abin da zai haifar da mummunar tasirin miyagun ƙwayoyi - ya zuwa yanzu yana da alƙawarin bayar da shawarar cewa ƙwayoyi na CGRP suna hana migraines kuma suna da hakuri.
A cikin nazarin daya, mahalarta 217 da ke samun raunin gudun hijira 4 zuwa 14 a wata, an yi watsi da su a cikin ƙananan ƙwayar cutar sau biyu a kowane mako na ko magungunan da ake kira LY2951742 ko placebo - sukari ko ruwan inuwa - na tsawon makonni 12.
(LY2951742 shi ne wanda ya saba da peptide na kwayiton (CGRP) - wannan yana nufin cewa yana ɗaura zuwa CGRP kuma yana kangewa ko ba shi da shi).
Sakamakon ya nuna cewa mahalarta wadanda suka karbi LY2951742 suna da karuwa mai yawa a cikin yawan ƙwayar cutar ta migraine lokacin da aka kwatanta da placebo. Har ila yau labari mai kyau shine cewa wannan magani ya samu lafiya da kuma jure wa da kyau ta hanyar batutuwa.
Hakanan an fada cewa illa mai lalacewa sun hada da:
- injin ciwon inje
- zafi na ciki
- ƙwayar cutar na numfashi na sama (misali mashako)
Wani magungunan da ake kira ALD403 - kuma wanda aka kwatanta da kwayoyin peptide - wanda aka kwatanta da kwayoyin halitta - an gwada shi a cikin mahalarta 163 da ke da kullun 5 zuwa 14 a wata daya. Rabin rabi na batutuwa sun sami karfin magani na 1000mg (ta hanyar maganin ƙwayar cutar), yayin da sauran rabi suka samu wuribo. An tsara batutuwa don watanni 6.
A lokacin makonni 5 zuwa 8, mahalarta wadanda suka karbi kwayoyi sun ga kashi 66 cikin dari na yawan kwanakin da suka sha wahala daga migraine zuwa kashi 52 cikin dari na wadanda suka sami placebo.
Har ila yau, a makonni 12, kashi 16 cikin 100 na marasa lafiya da suka karbi magani sun kasance kyauta ne kyauta ba tare da zamo ba daga wadanda suka karbi wuri.
A ƙarshe, wani magani, wanda aka gudanar a karkashin fata (injection subcutaneous) da ake kira AMG 334 - wani antibody wanda ke ɗaure ga mai karɓa na CGRP (shafin yanar gizon CGRP) - an samu kwanan nan don hana magunguna. Kamar sauran magungunan biyu, AMG 334 ya yi haƙuri sosai. Abubuwa masu rinjaye mafi yawan sune:
- sanyi bayyanar cututtuka
- gajiya
- ciwon kai ko ƙaura (tafi siffar - ƙananan, kashi 3 cikin dari zuwa 1 bisa dari a cikin rukuni na placebo)
- tashin zuciya
- ƙwayar cutar na numfashi na sama (misali mashako).
Layin Ƙasa
Wadannan sakamako ne masu ban sha'awa ga al'ummar migraine. Duk da haka, binciken da ya fi girma na III - binciken da ya fi girma kuma tabbatar da ƙididdiga na binciken ilimin lokaci na II - dole ne a yi kafin wadannan kwayoyi za a samu ga marasa lafiya.
Sources:
Bigal ME, Walter S, Rahoton AM. Calcitonin gene-bayar da rahoton peptide (CGRP) da kuma fahimtar halin yanzu na migraine da kuma yanayin ci gaba. Ciwon kai . 2013; 53 (8): 1230-44.
Durham PL. Calcitonin Gene-Related Peptide (CGRP) da Migraine. Ciwon kai. 2006 (46) (Sanya 1): S3-S8.
Goadsby PJ, & Edvinsson L. Tsarin kwayoyin halitta da ƙaura: binciken da ke nuna cututtuka na cerebrovascular da kuma neuropeptide da aka gani a cikin mutane da cats. Ann Neurol. 1993 Janairu 33 (1): 48-56.
Sakamakon farko na ALD403, Sabuwar Magunin Binciken Nazari don Rigakafin Migraine. (nd). A {asashen Ciwon Kai na Amirka. Sake dawowa ranar 18 ga Mayu, 2014.
Sun H et al. Tsaro da inganci na AMG 334 don kare rigakafi na episodic: wani baƙi, mai makantar makafi, wuri mai sarrafawa, lokaci 2 gwaji. Lancet Neurol. 2016; 15 (4): 382-90.